Mode
Text Size
Log in / Sign up

Multiple myeloma diagnosis associated with markedly increased hematologic second primary malignancies in 279,894 patientsMultiple myeloma patients show higher risk of second blood cancers, review finds

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider intensified surveillance for hematologic second primary malignancies in multiple myeloma patients given the markedly increased risk.

This systematic review and meta-analysis pooled data from 15 studies involving 279,894 patients with multiple myeloma to assess the risk of second primary malignancies (SPMs) relative to the general population. The analysis utilized standardized incidence ratios (SIRs) to compare observed versus expected cases across various malignancy types. No meaningful variation in risk was observed based on diagnostic period, latency, age, or sex subgroups.

Regarding overall risk, the study found that the risk of SPMs and solid tumor SPMs was not significantly higher than in the general population. However, the risk of hematologic SPMs was markedly increased, with a pooled SIR of 2.91 (95% CI: 1.57–5.41). Specific malignancies demonstrated a mixed pattern, with some showing higher risks and others showing reduced risks, though individual effect sizes for these specific types were not reported.

Safety and tolerability data, including adverse events or discontinuations, were not reported in the source studies. As an observational meta-analysis, these findings describe associations rather than causation. Absolute risks were not provided, limiting direct application to individual patient counseling. The practice relevance underscores the need for tumor-specific surveillance, particularly for hematologic SPMs and selected solid tumors, rather than applying uniform follow-up strategies.

Researchers analyzed data from 15 previous studies involving nearly 280,000 people with multiple myeloma. They wanted to understand whether having this blood cancer affects a person's risk of developing a completely different second cancer later on. They compared the cancer rates in these patients to what would be expected in the general population.

The main finding was that the overall risk of developing any second primary cancer was not significantly higher for multiple myeloma patients. However, when looking at specific cancer types, the picture was more complex. The risk of developing a second blood cancer was markedly increased—about three times higher than expected. The analysis also identified specific solid tumors where risk was either increased or decreased.

This was an observational meta-analysis, which means it combined existing data to look for patterns and associations. It cannot prove that multiple myeloma causes these second cancers. The study did not report absolute risk numbers, so we don't know how common these second cancers actually are. The authors suggest that cancer follow-up strategies should consider these site-specific risks rather than using a one-size-fits-all approach.

Readers should understand this research identifies a pattern that needs further study, not a definitive cause-and-effect relationship. People with multiple myeloma should continue with their recommended follow-up care and discuss any concerns about cancer risk with their healthcare team.

What this means for you:
Multiple myeloma linked to higher risk of second blood cancers in analysis, but more research needed to understand why.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
BackgroundWith improving survival in multiple myeloma (MM), second primary malignancies (SPMs) remain an important issue in long-term care. This study assessed the risk of SPMs among individuals with MM.MethodsWe systematically searched EMBASE, PubMed, and the Cochrane Library for studies published up to August 15, 2025, and pooled standardized incidence ratios (SIRs) to compare SPM risks in MM patients with those in the general population.ResultsOf 1602 records screened, 15 studies comprising 279,894 MM patients met the inclusion criteria. The overall risks of SPMs and solid tumors were not significantly higher than those in the general population. In contrast, the risk of hematologic SPMs was markedly increased (SIR = 2.91; 95% CI: 1.57–5.41). Higher risks were identified for several malignancies, including non-Hodgkin lymphoma (NHL), myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), mesothelioma, skin cancer, melanoma, endocrine tumors, and thyroid cancer. Reduced risks were observed for chronic lymphocytic leukemia (CLL), head and neck cancer, tracheal/bronchial/lung cancer, bladder cancer, and breast cancer. Subgroup analyses showed no meaningful variation by diagnostic period, latency, age, or sex.ConclusionThese findings demonstrate that MM have a distinct SPM pattern, underscoring the need for tumor-specific surveillance with particular attention to hematologic SPMs and selected solid tumors. The lower incidence of breast cancer is an unexpected and potentially informative signal that could help guide future research. Overall, follow-up strategies should be shaped by site-specific risks rather than applied uniformly across all SPMs.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251087056.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.